Prospective observational study to investigate demography, clinical course and biomarkers of progressive supranuclear palsy.

Recruiting

• Conditions: G23.1; Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]

• Registration Number: DRKS00022436
• Lead Sponsor: Klinikum rechts der Isar der TU München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-08-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Clinical diagnosis of suggestive of, possible or probable PSP according to the MDS-PSP diagnostic criteria (Höglinger et al., 2017)

Exclusion Criteria

Exclusion criteria are equivalent to the MDS.PSP diagnostic criteria

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of this study is to set up a clinical register to study natural history, disease course, genetics and pathophysiology of progressive supranuclear palsy. In the long term, analysis of the data collected should improve early diagnosis and prediction of disease progression.

Secondary Outcome Measures

Name	Time	Method
A secondary endpoint of the ProPSP study is to build a trial-ready cohort.